CD4+ T cell markers associated with Treatment Outcomes in Tuberculosis: A Sub-analysis of a Phase IIB Trial of Acetylsalicylic acid and Ibuprofen as Adjunctive Therapy
Clicks: 10
ID: 322925
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
2.7
/100
10 views
3 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #229 of 432 articles by views in The Journal of infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 432 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
BACKGROUND: Adjunctive host-directed therapies (HDT) may improve treatment outcomes in tuberculosis (TB). Affordable repurposed drugs can be quickly implemented in clinical practice; however, predictive biomarkers are essential for determining their potential effectiveness. METHODS: 72 patients (35.2% people with HIV) from South Africa with drug-sensitive pulmonary TB, recruited to the SMA-TB clinical trial of adjunctive acetylsalicylic acid (ASA) and ibuprofen (IBU), were included. CD4+ T cell subsets and Mtb-specific CD4+ T cell responses were analysed by flow cytometry at baseline, week 2, week 8 and week 24 and tested as predictors for microbiological, clinical and radiological outcomes. RESULTS: Most TB patients experienced a fast sputum culture conversion and good clinical and radiological outcomes by week 24, regardless of intervention or HIV co-infection. During TB therapy, fractions of Mtb-specific polyfunctional CD4+ T cells, Th1 and Th1/Th17 subsets, and CD153 expression increased, whereas Ki67+HLA-DR+ CD4+ T cells declined. No statistically significant differences were identified between the ASA or IBU groups and placebo for any defined outcome. Still, higher baseline fractions of polyfunctional and CD153-expressing CD4+ T cells were associated with fast sputum culture conversion in the ASA and placebo arms. CONCLUSIONS: CD4+ T cell subsets show promise as markers of disease severity and potential predictors of microbiological, clinical, and radiological outcomes in treated TB. However, the present findings are insufficient to support the routine use of ASA or IBU in adjunctive HDT regimens, and larger, targeted studies are warranted.
| Reference Key |
openalex_W7171636565
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Noelia Alonso‐Rodríguez, Iselin Høgbakk Edlund, Hans Christian D. Aass, Chiara Sopegno, Judith Farrés, Nino Gogichadze, Lilibeth Arias, Kaori L. Fonseca, Kennedy Otwombe, Ziyaad Waja, Tumelo Moloantoa, Natasha Pillay, Thabiso Seiphetlo, Neil Martinson, Cristina Vilaplana, Anne Ma Dyrhol‐Riise |
| Journal | The Journal of infectious diseases |
| Year | 2026 |
| DOI |
10.1093/infdis/jiag380
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.